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Introduction 
 
In leiomyosarcoma (LMS) abnormal 
vaginal bleeding is the most common 
reported symptom in patients (56%), 
followed by pelvic mass (54%), and 
pain (22%).1 LMS is often hard to 
diagnosis on a uterine biopsy 
because it does not originate in the 
endometrium and may not invade 
into the cavity. In reality LMS is only 
detectable by endometrial biopsy in 
33% of cases.2 Non-specific 
symptoms as well as difficulty in 
diagnosis being made by biopsy, 
means that many LMS tumors are 
often mistaken for fibroids 
preoperatively. 
 
If LMS is known preoperatively then 
a total abdominal hysterectomy with 
bilateral salpingo-oopherectomy 
(TAH/BSO) and evaluation of the 
abdominal and pelvic cavities can by 
undertaken. While routine pelvic and 
paraaortic lymphadenectomies are 
controversial in LMS, it may be 
required in certain circumstances.  
Unfortunately, a simple hysterectomy 
or even myomectomy is often 
performed for what is believed to be 
a benign process.  
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Leiomyosarcoma is a rare tumor that 
accounts for only 1% of all uterine 
malignancies.1 In the past it was 
believed to be the most common 
uterine sarcoma; however a more 
recent report shows that it is second 
behind mixed mesodermal stromal 
sarcoma which accounts for 66% of 
uterine sarcomas.3 LMS can arise 
from either the smooth muscle cells 
of the myometrium or from within a 
leiomyomata (fibroid) itself .3 
 
LMS often spreads by the 
hematogenous route with lung or 
pleural involvement as one of the 
most frequent metastatic sites. Five 
year overall survival rates for LMS by 
stage are: stage I = 60%; stage II 
=35%; stage III 26%; and stage IV 
13%.4   
  
 
Case 
 
A 45-year-old G2, P2 presented to 
her primary Ob/Gyn for a 2-month 
history of worsening dysfunctional 
uterine bleeding. An ultrasound was 
performed and it was felt that this 
patient had a 7cm fibroid 
(leiomyomata). The patient 
subsequently underwent total 
abdominal hysterectomy with 
bilateral salpingoopherectomy. Final 
pathology (fig. 1) showed a LMS with 
greater than 15 mitotic figures per 10 
high power fields 
(>15mitosis/10HPF). Areas of 
coagulative necrosis were also 
noted; however, there was no 
vascular space involvement. Further 
tests confirmed this tumor had both 
estrogen and progesterone 
receptors.  
 
 
 
 
Figure 1 
 
Histologically, the uterus displays 
hypercellularity and marked nuclear atypia with 
several mitotic figures, consistent with the 
diagnosis of leiomyosarcoma. (Hematoxylin and 
Eosin, original magnification: 200X)  
 
 
Figure  2 
 
FDG-PET scan of chest, with suspicious lesion in 
black 
 
This patient’s care was subsequently 
transferred to a Gynecologic 
Oncologist at The West Clinic in 
Memphis, Tennessee. Post-
operatively the patient did very well, 
and a computed tomography (CT) 
scan of the patient’s chest, 
abdomen, and pelvis were obtained. 
On chest CT three nodules were 
noted. Two of these appeared to be 
benign granulomas, but the third 
nodule had an indeterminate 
appearance. A positron emission 
tomography scan (PET) using [18F]-
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fluorodeoxyglucose (FDG) was 
performed (fig 2).  PET scan 
revealed a hypermetabolic lesion 
with a standardized uptake value 
(SUV) of 4.1.  Subsequently a CT 
guided percutaneous needle biopsy 
was performed on the right 
pulmonary nodule (fig. 3). The lung 
biopsy was examined and compared 
to the patient’s original hysterectomy 
slides, and metastatic LMS was 
confirmed (fig. 4).  
 
  
Figure 3 
 
CT of chest with suspicious 9mm nodule during 
biopsy 
 
A small pneumothorax was noted 
after the biopsy procedure. The 
pneumothorax resolved 
spontaneously with time under 
observation. The patient underwent 
chemotherapy using a sarcoma 
protocol with Adriamycin and 
Ifosfamide. She was re-assessed 
after 2-cyles for consideration of 
ablation or resection of the lung 
nodule; however, the lesion 
decreased in size from 9mm to less 
than 3mm and was not felt to be 
amenable to resection. The patient 
completed 6 cycles of the above 
chemotherapy with resolution of the 
lung lesion. The patient is currently 
under observation. 
 
 
 
Figure 4 
 
The bizarre cellular atypia and brisk mitotic rate 
of the primary lesion are recapitulated in this 
biopsy from the lung metastases. (Hematoxylin 
and Eosin, original magnification: 200X) 
 
 
DISCUSSION  
 
Positron Emission Tomography 
(PET) is now commonplace in the 
realm of oncology, and 
Fludeoxyglucose (FDG) has become 
a common tracer. FGD is a glucose 
analogue that is readily taken up by 
cells using the glucose transporter, 
in particular by tumor cells.6 Tumor 
cells have a higher metabolic rate 
then normal cells causing greater 
FDG uptake.7 FDG cannot be 
metabolized like glucose, and 
therefore is “trapped” within the cell. 
These areas of increased FDG 
uptake, or increased SUV, are used 
to show a 3 dimensional image of 
the body with areas of concern 
highlighted.  
Proceedings in Obstetrics and Gynecology, 2011 July; 2(1):14 
 
PET in detection of metastatic leiomyosarcoma   4 
 
 
FDG-PET has been used 
successfully in other gynecological 
malignancies. Hubner et al. in his 
study of ovarian cancer and FDG-
PET found PET had 93% sensitivity 
and 82% specificity in primary 
ovarian tumors. He also showed that 
when CT and FDG-PET were 
combined they had a 95% positive 
predictive value and a 100% 
negative predictive value.8  
 
FDG-PET has also been used 
successfully in cervical cancer. 
Sugawara showed that FDG-PET 
correctly identified 16 of 21 known 
cervical cancers. These results were 
improved when post bladder void 
scans was done and correctly 
identified 11 of 11 patients.9 FDG is 
excreted in the urine, and therefore 
the bladder will concentrate the 
tracer making pelvic images difficult 
to evaluate.  
 
FDG-PET has already been used 
successfully in the preoperative 
assessment of uterine sarcomas. A 
study done in Osaka, Japan looked 
at the preoperative scans of 5 
patients with uterine sarcoma. Of 
these 5 patients with pathology 
confirmed sarcoma all 5 patients had 
positive (SUV >2.5) FDG-PET scans. 
3 of these reported 5 patients had 
LMS, 1 had carcinosarcoma, and the 
last one had endometrial stromal 
sarcoma.10   
 
Another preoperative study done by 
Nagamatsu et al. showed an 
average SUV of 4.2 in their group of 
4 LMS.11  They showed that SUV 
uptake in endometrial carcinoma, 
carcinosarcoma, and LMS had a 
higher SUV than benign 
leiomyomas.  They further showed 
that the combination of FDG-PET 
and serum LDH had improved 
sensitivity and specificity than FDG-
PET alone for detecting LMS. 
 
Kao et al. looked at the use of FDG-
PET and CT combination to detect 
recurrent disease in LMS.12  Among 
11 patients they found the 
combination scan had near perfect 
accuracy.  However, 2 patients had 
recurrence only detected by the CT 
portion and not by PET. 
 
 To our knowledge this is the only 
reported case of FDG-PET being 
used in the postoperative evaluation 
of a patient with LMS and a 
suspicious lung mass. Our case 
shows there may be a place for PET 
scans in the post-op surveillance of 
LMS. This method would be ideally 
suited, considering the metastatic 
spread pattern of LMS. Unfortunately 
due to the rarity of this disease a 
prospective evaluation of this 
modality would not be practical.  
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